Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Fairmount Healthcare Fund IIDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 05/11 | 05/13 | 1,176,470 sh | $17.00 | $19,999,990 | +30.1% |
Fairmount Funds ManagementDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 05/11 | 05/13 | 1,176,470 sh | $17.00 | $19,999,990 | +30.1% |
Fairmount Healthcare Fund II GPDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 05/11 | 05/13 | 1,176,470 sh | $17.00 | $19,999,990 | +30.1% |
Jennifer TousignantChief Legal Officer | Viridian Therapeutics, Inc.\DEVRDN | Open-market sale | 25/12/31 | 01/02 | 2,272 sh | $31.16 | $70,795.52 | −100.0% |
Fairmount Healthcare Fund IIDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 25/10/23 | 25/10/27 | 454,545 sh | $22.00 | $9,999,990 | +13.1% |
Fairmount Funds ManagementDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 25/10/23 | 25/10/27 | 454,545 sh | $22.00 | $9,999,990 | +13.1% |
Fairmount Healthcare Fund II GPDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 25/10/23 | 25/10/27 | 454,545 sh | $22.00 | $9,999,990 | +13.1% |
Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/09/27 | 24/09/30 | 5,000 sh | $23.41 | $117,050 | +500.0% | |
Stephen F. MahoneyPresident and CEO | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/09/27 | 24/09/30 | 21,400 sh | $23.33 | $499,262 | No record |
Fairmount Healthcare Fund IIDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/09/13 | 24/09/17 | 1,600,000 sh | $18.75 | $30,000,000 | +86.7% |
Fairmount Funds ManagementDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/09/13 | 24/09/17 | 1,600,000 sh | $18.75 | $30,000,000 | +86.7% |
Fairmount Healthcare Fund II GPDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/09/13 | 24/09/17 | 1,600,000 sh | $18.75 | $30,000,000 | +86.7% |
Fairmount Healthcare FundDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/01/22 | 24/01/24 | 476,190 sh | $21.00 | $9,999,990 | +34.9% |
Fairmount Healthcare Fund IIDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/01/22 | 24/01/24 | 476,190 sh | $21.00 | $9,999,990 | +34.9% |
Fairmount Funds ManagementDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/01/22 | 24/01/24 | 476,190 sh | $21.00 | $9,999,990 | +34.9% |
Fairmount Healthcare Fund II GPDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/01/22 | 24/01/24 | 476,190 sh | $21.00 | $9,999,990 | +34.9% |
Fairmount Healthcare Fund GPDirector | Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 24/01/22 | 24/01/24 | 476,190 sh | $21.00 | $9,999,990 | +34.9% |
Viridian Therapeutics, Inc.\DEVRDN | Open-market sale | 23/06/15–23/06/16 | 23/06/20 | 2,296 sh2 trades | $28.02avg. | $64,342.83 | −7.1% | |
Viridian Therapeutics, Inc.\DEVRDN | Open-market sale10b5-1 plan | 23/06/02–23/06/06 | 23/06/06 | 7,500 sh3 trades | $24.82avg. | $186,136.24 | −20.0% | |
Viridian Therapeutics, Inc.\DEVRDN | Open-market buy | 23/04/12 | 23/04/12 | 4,000 sh | $25.37 | $101,480 | +1.6% |